METHOD OF DIFFERENTIATING HEPATIC FIBROSIS IN CHRONIC VIRAL HEPATITIS B AND AUTOIMMUNE LIVER INJURIES Russian patent published in 2019 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to medicine and is intended for differential diagnosis of hepatic fibrosis in viral hepatitis B (HBV) and autoimmune liver injuries (ALI). Blood plasma is used to determine concentration of cytokines CCL8/MCP-2, CXCL10/IP-10, IFN γ. At the first stage, the concentration of CCL8/MCP-2 is evaluated, with values of which ≥22.9 pg/ml of the patient must be attributed to the first subgroup with advantage HBV, with values <22.9 pg/ml – to the second subgroup, with advantage ALI, then evaluating CXCL10/IP-10, if its value <660.57 pg/ml for the first subgroup is diagnosed HBV, ≥660.57 pg/ml – diagnosed ALI, for the second subgroup, if CXCL10/IP-10<376.4 pg/ml is diagnosed HBV, if ≥376.4, additional analysis of IFN γ is performed if IFN γ≥7.19 pg/ml is diagnosed HBV, and if <7.19 – ALI.

EFFECT: method provides higher accuracy of differential diagnosis of hepatic fibrosis.

1 cl, 1 dwg, 4 ex